RESUMEN
PURPOSE: Enzymolysis clearance strategy, characterized by releasing the non-reabsorbable radioactive fragment under the specific cleavage of enzymes, is confirmed to be a safe and effective way to reduce the renal radioactivity accumulation in mice. However, the effectiveness of this strategy in humans remains unknown. Human epidermal growth factor receptor 2 (HER2) is overexpressed in various types of tumors, and radiolabeled HER2 Affibody is believed to be an attractive tool for HER2-targeted theranostics. However, its wide application is limited by the high and persistent renal uptake. In this study, we intend to validate the effectiveness of enzymolysis clearance strategy in reducing renal accumulation by using a modified HER2 Affibody. MATERIALS AND METHODS: A new HER2 Affibody ligand, NOTA-MVK-ZHER2:2891, containing a cleavable Met-Val-Lys (MVK) linker was synthesized and labeled with 68Ga. The microPET imaging study was performed in SKOV-3 tumor mice to assess the uptakes of the control ligand and the MVK one in tumors and kidneys. Seven healthy volunteers were included for biodistribution and dosimetric studies with both the control and MVK ligands performed 1 week apart. Urine and blood samples from healthy volunteers were collected for in vivo metabolism study of the two ligands. Four HER2-positive and two HER2-negative patients were recruited for [68Ga]Ga-NOTA-MVK-ZHER2:2891 PET/CT imaging at 2 and 4 h post-injection (p.i.). RESULTS: [68Ga]Ga-NOTA-MVK-ZHER2:2891 was stable both in PBS and in mouse serum. MicroPET images showed that the tumor uptake of [68Ga]Ga-NOTA-MVK-ZHER2:2891 was comparable to that of [68Ga]Ga-NOTA-ZHER2:2891 at all the time points, while the kidney uptake was significantly reduced 40 min p.i. (P < 0.05). The biodistribution study in healthy volunteers showed that the kidney uptake of MVK ligand was significantly lower than that of the control ligand at 1 h p.i. (P < 0.05), with the SUVmean of 34.3 and 45.8, respectively, while the uptakes of the two ligands in the other organs showed negligible difference. The effective doses of the MVK ligand and the control one were 26.1 and 28.7 µSv/MBq, respectively. The enzymolysis fragment of [68Ga]Ga-NOTA-Met-OH was observed in the urine samples of healthy volunteers injected with the MVK ligand, indicating that the enzymolysis clearance strategy worked in humans. The PET/CT study of patients showed that the range of SUVmax of HER2-positive lesions was 9.4-21, while that of HER2-negative lesions was 2.7-6.2, which suggested that the MVK modification did not affect the ability of ZHER2:2891 structure to bind with HER2. CONCLUSION: We for the first time demonstrated that enzymolysis clearance strategy can effectively reduce renal radioactivity accumulation in humans. This strategy is expected to decrease renal radiation dose of peptide and small protein-based radiotracers, especially in the field of radionuclide therapy.
Asunto(s)
Radioisótopos de Galio , Riñón , Neoplasias , Receptor ErbB-2 , Animales , Femenino , Humanos , Ratones , Línea Celular Tumoral , Riñón/metabolismo , Riñón/efectos de la radiación , Tomografía Computarizada por Tomografía de Emisión de Positrones , Tomografía de Emisión de Positrones , Radiofármacos/farmacocinética , Radiofármacos/química , Receptor ErbB-2/metabolismo , Proteínas Recombinantes de Fusión/farmacocinética , Distribución Tisular , Neoplasias/diagnóstico por imagen , Neoplasias/genéticaRESUMEN
PURPOSE: Imaging assessment of abdominopelvic tumor burden is crucial for debulking surgery decision in ovarian cancer patients. This study aims to compare the efficiency of [68Ga]Ga-FAPI-04 FAPI PET and MRI-DWI in the preoperative evaluation and its potential impact to debulking surgery decision. METHODS: Thirty-six patients with suspected/confirmed ovarian cancer were enrolled and underwent integrated [68Ga]Ga-FAPI-04 PET/MRI. Nineteen patients (15 stage III-IV and 4 I-II stage) who underwent debulking surgery were involved in the diagnostic efficiency analysis. The images of [68Ga]Ga-FAPI-04 PET and MRI-DWI were visually analyzed respectively. Immunohistochemistry on FAP was performed in metastatic lesions to investigate the radiological missing of [68Ga]Ga-FAPI-04 PET as well as its different performance in primary debulking surgery (PDS) and interval debulking surgery (IDS) patients. Potential imaging impact on management was also studied in 35 confirmed ovarian cancer patients. RESULTS: [68Ga]Ga-FAPI-04 PET displayed higher sensitivity (76.8% vs.59.9%), higher accuracy (84.9% vs. 80.7%), and lower missing rate (23.2% vs. 40.1%) than MRI-DWI in detecting abdominopelvic metastasis. The diagnostic superiority of [68Ga]Ga-FAPI-04 PET is more obvious in PDS patients but diminished in IDS patients. [68Ga]Ga-FAPI-04 PET outperformed MRI-DWI in 70.8% abdominopelvic regions (17/24), which contained seven key regions that impact the resectability and surgical complexity. MRI-DWI hold advantage in the peritoneal surface of the bladder and the central tendon of the diaphragm. Of the contradictory judgments between the two modalities (14.9%), [68Ga]Ga-FAPI-04 PET correctly identified more lesions, particularly in PDS patients (73.8%). In addition, FAP expression was independent of lesion size and decreased in IDS patients. [68Ga]Ga-FAPI-04 PET changed 42% of surgical planning that was previously based on MRI-DWI. CONCLUSION: [68Ga]Ga-FAPI-04 PET is more efficient in assisting debulking surgery in ovarian cancer patients than MRI-DWI. Integrated [68Ga]Ga-FAPI-04 PET/MR imaging is a potential method for planning debulking surgery in ovarian cancer patients.
Asunto(s)
Procedimientos Quirúrgicos de Citorreducción , Neoplasias Ováricas , Tomografía de Emisión de Positrones , Quinolinas , Humanos , Femenino , Neoplasias Ováricas/diagnóstico por imagen , Neoplasias Ováricas/cirugía , Neoplasias Ováricas/patología , Persona de Mediana Edad , Tomografía de Emisión de Positrones/métodos , Anciano , Procedimientos Quirúrgicos de Citorreducción/métodos , Adulto , Imagen de Difusión por Resonancia Magnética , Imagen por Resonancia Magnética , Imagen Multimodal/métodos , Cirugía Asistida por Computador/métodos , Radioisótopos de GalioRESUMEN
OBJECTIVE: This study utilized a data-driven Bayesian model to automatically identify distinct latent disease factors represented by overlapping glucose metabolism patterns from 18F-Fluorodeoxyglucose PET (18F-FDG PET) to analyze heterogeneity among patients with TLE. METHODS: We employed unsupervised machine learning to estimate latent disease factors from 18F-FDG PET scans, representing whole-brain glucose metabolism patterns in seventy patients with TLE. We estimated the extent to which multiple distinct factors were expressed within each participant and analyzed their relevance to epilepsy burden, including seizure onset, duration, and frequency. Additionally, we established a predictive model for clinical prognosis and decision-making. RESULTS: We identified three latent disease factors: hypometabolism in the unilateral temporal lobe and hippocampus (factor 1), hypometabolism in bilateral prefrontal lobes (factor 2), and hypometabolism in bilateral temporal lobes (factor 3), variably co-expressed within each patient. Factor 3 demonstrated the strongest negative correlation with the age of onset and duration (r = - 0.33, - 0.38 respectively, P < 0.05). The supervised classifier, trained on latent disease factors for predicting patient-specific antiepileptic drug (AED) responses, achieved an area under the curve (AUC) of 0.655. For post-surgical seizure outcomes, the AUC was 0.857, and for clinical decision-making, it was 0.965. CONCLUSIONS: Decomposing 18F-FDG PET-based phenotypic heterogeneity facilitates individual-level predictions relevant to disease monitoring and personalized therapeutic strategies.
Asunto(s)
Epilepsia del Lóbulo Temporal , Fluorodesoxiglucosa F18 , Tomografía de Emisión de Positrones , Humanos , Epilepsia del Lóbulo Temporal/diagnóstico por imagen , Epilepsia del Lóbulo Temporal/metabolismo , Masculino , Femenino , Adulto , Pronóstico , Persona de Mediana Edad , Fenotipo , Toma de Decisiones Clínicas/métodos , Adulto Joven , Aprendizaje Automático no Supervisado , Teorema de Bayes , Radiofármacos , Anticonvulsivantes/uso terapéutico , AdolescenteRESUMEN
The quantitative structure-activity relationship (QSAR) is one of the most popular methods for the virtual screening of new drug leads and optimization. Herein, we collected a dataset of 955 MIC values of pleuromutilin derivatives to construct a 2D-QSAR model with an accuracy of 80% and a 3D-QSAR model with a non-cross-validated correlation coefficient (r2) of 0.9836 and a cross-validated correlation coefficient (q2) of 0.7986. Based on the obtained QSAR models, we designed and synthesized pleuromutilin compounds 1 and 2 with thiol-functionalized side chains. Compound 1 displayed the highest antimicrobial activity against both Staphylococcus aureus ATCC 29213 (S. aureus) and Methicillin-resistant Staphylococcus aureus (MRSA), with minimum inhibitory concentrations (MICs) < 0.0625 µg/mL. These experimental results confirmed that the 2D and 3D-QSAR models displayed a high accuracy of the prediction function for the discovery of lead compounds from pleuromutilin derivatives.
Asunto(s)
Diterpenos , Staphylococcus aureus Resistente a Meticilina , Compuestos Policíclicos , Pleuromutilinas , Antibacterianos/química , Relación Estructura-Actividad Cuantitativa , Staphylococcus aureus , Diterpenos/química , Compuestos Policíclicos/farmacología , Pruebas de Sensibilidad Microbiana , Relación Estructura-Actividad , Simulación del Acoplamiento MolecularRESUMEN
Coronavirus disease 2019 (COVID-19) is a serious threat to public health and is in urgent need of specific drugs. Meplazumab, a humanized monoclonal antibody targeting CD147, was confirmed to competitively block the binding between the spike of syndrome coronavirus 2 (SARS-CoV-2) and CD147, making meplazumab a promising candidate drug for COVID-19. In this study, biodistribution and dosimetry of 131I-labeled meplazumab were performed to further evaluate its potential as a therapeutic drug for COVID-19. 131I-meplazumab was both safe and tolerant in mice and healthy volunteers. A biodistribution study was performed in normal mice, and blood samples were used for pharmacokinetic analysis. Three healthy volunteers were included and subjected to single-photon-emission computed tomography (SPECT) imaging of 131I-meplazumab within 2 weeks. The distribution in mice and humans was consistent with the in vivo distribution of CD147. Biodistribution and SPECT imaging results exhibited that the liver was the organ with the highest uptake for both mice and humans. Deiodination of 131I-meplazumab can be observed in vivo, and taking Lugol's solution can protect the thyroid gland effectively. The pharmacokinetic characteristics of 131I-meplazumab in mice and humans best fit the two-compartment model. The clearance half-life (T1/2ß) in mice and humans was 117.4 and 223.5 h, respectively. The results indicated that its pharmacokinetic properties in vivo were ideal. The effective dose calculated from healthy volunteers was 0.811 ± 0.260 mSv·MBq-1, which was twice the value calculated from mice. It was safe and feasible to perform human clinical imaging experiments using a diagnostic dose of 131I-meplazumab after thyroid closure by Lugol's solution. This study will provide more experimental basis for advancing the clinical translation of meplazumab and will be valuable in evaluating therapeutic interventions for patients with COVID-19, as well as providing a reference for clinical translation studies of other antibody drugs.
Asunto(s)
COVID-19 , Humanos , Animales , Ratones , Distribución Tisular , SARS-CoV-2 , Tomografía Computarizada de Emisión de Fotón Único/métodos , RadiometríaRESUMEN
P137 is a novel oxalyldiaminopropionic acid-urea-based prostate-specific membrane antigen (PSMA) targeting agent. This study compared the uptake patterns of 68Ga-P137 and the FDA-approved PET tracer 68Ga-PSMA-11 for diagnosing prostate cancer (PCa). Sixteen patients suspected of PCa were scanned by 68Ga-PSMA-11 and 68Ga-P137 PET/CT, respectively, followed by prospective analysis. The tumor-to-background ratio was calculated using normal prostate tissue, blood pool, muscle, and urine as backgrounds. Pathology or follow-up results were used to analyze uptake patterns of benign/malignant lesions and various organs. Thirteen patients were diagnosed with PCa and three with benign prostate diseases (BPD). The number and location of primary lesions, lymph node metastasis (LNM) (n = 25), bone metastasis (n = 30), and liver metastasis (n = 3) detected by the two tracers were identical. Maximum standardized uptake value (SUVmax), tumor/normal prostate ratio, as well as semiquantitative miPSMA-ES and PRIMARY diagnostic scores (P all >0.05) showed similar uptake levels of primary lesions between 68Ga-P137 and 68Ga-PSMA-11. Compared to 68Ga-P137, the SUVmax of 68Ga-PSMA-11 was significantly higher for bone metastasis, LNM, and liver metastasis (14.9 ± 7.2 vs 9.1 ± 4.4, 14.4 ± 5.0 vs 7.5 ± 2.4, 13.9 ± 2.0 vs 8.8 ± 2.4, P all <0.05). One-hour postinjection, SUVmax of the duodenum (9.4 ± 2.1 vs 16.2 ± 6.1), kidney (19.4 ± 4.3 vs 45.6 ± 20.9), and urine (14.1 ± 7.1 vs 42.1 ± 25.9) were significantly lower for 68Ga-P137 than for 68Ga-PSMA-11 (P all <0.05), whereas the radioactivity accumulation of blood pool and muscle (3.9 ± 0.5 vs 1.6 ± 0.4, 1.0 ± 0.1 vs 0.6 ± 0.1, P all <0.05) of 68Ga-P137 was significantly higher than 68Ga-PSMA-11. The uptake level of 68Ga-P137 has no significant difference from that of 68Ga-PSMA-11 in prostate primary lesions, and their imaging performances are visually equivalent for both primary and metastatic lesions, despite a higher blood pool and muscle background and a lower uptake in metastatic lesions. Due to the lower urine excretion of 68Ga-P137, primary prostate lesions near the urine can potentially be displayed clearer than 68Ga-PSMA-11.
Asunto(s)
Neoplasias Óseas , Neoplasias Hepáticas , Neoplasias de la Próstata , Masculino , Humanos , Radioisótopos de Galio , Tomografía Computarizada por Tomografía de Emisión de Positrones/métodos , Neoplasias de la Próstata/diagnóstico por imagen , Neoplasias de la Próstata/patología , Metástasis Linfática , Neoplasias Óseas/secundarioRESUMEN
BACKGROUND Plantar pressure analysis is widely used in the study of knee osteoarthritis (KOA). The present study aimed to investigate the static and dynamic plantar pressure distribution in patients with different stages of unilateral KOA using the Footscan® platform system. MATERIAL AND METHODS We recruited 94 patients aged 61.75±7.23 years old with different stages of unilateral KOA for static and dynamic analysis using the Footscan® platform system. The static pressure (%) of the left, right, anterior, posterior, and the pelvic rotation (°) was assessed. The peak pressure (PP, kPa) was investigated in 10 areas of the foot: medial heel (MH), lateral heel (LH), midfoot (MF), first to fifth metatarsals (M1-M5), hallux (T1), and toes 2-5 (T2-5). The correlation between KOA stages and plantar pressure distributions was investigated. RESULTS The results revealed that static pressure on the unaffected side and pelvic rotation were positively correlated with KOA stages. In addition, there was a positive correlation between KOA stages and PP of M5, MF, and LH zones on the affected side and PP of M2, M3, and M4 zones on the unaffected side, and a negative correlation between KOA stages and PP of T1 and T2-5 zones on the affected side. CONCLUSIONS With the progression of KOA, static plantar pressure tends to distributed on the unaffected side, and the dynamic plantar pressure tends to be distributed laterally on both feet. The plantar pressure distributions in unilateral KOA patients are abnormal and are closely related to the severity of KOA.
Asunto(s)
Osteoartritis de la Rodilla , Humanos , Persona de Mediana Edad , Anciano , Marcha , Presión , Pie , TalónRESUMEN
Previous studies have suggested strong antifibrotic activity of curcumol in the liver; the underlying mechanisms of which, however, remain largely unknown. Aiming to investigate the role of curcumol in regulating early and advanced liver fibrosis, we designed a rat model with advanced liver fibrosis and cell model with an initial fibrotic stage. Model rats induced by CCl4 and alcohol presented advanced liver fibrosis with complete fibrous septa. The administration of curcumol (25 mg/kg or 50 mg/kg) resulted in reversal of liver fibrosis. Leptin-administrated liver sinusoidal endothelial cells presented defenestration and basement membrane components deposition, including laminin (LN) and type IV collagen (Col IV), the characteristics of capillarization by scanning electron microscopy and immunofluorescence assays. After treatment with curcumol (12.5, 25, or 50 mg/L), defenestration was restored and the levels of LN and Col IV were decreased, consistent with the rat model. Quantitative polymerase chain reaction and Western blot results revealed that increased levels of urokinase plasminogen activator (uPA)/ uPA receptor (uPAR) were observed both in vivo and in vitro, curcumol significantly reduced uPA/uPAR at both the mRNA and protein levels. Reduction of uPA/uPAR may be synergistic with matrix metallopeptidase 13 to reverse liver fibrogenesis. In conclusion, curcumol protects liver from phenotypic changes in the early and advanced fibrogenesis, possibly through uPA/uPAR pathway.
Asunto(s)
Cirrosis Hepática/tratamiento farmacológico , Sesquiterpenos/uso terapéutico , Activador de Plasminógeno de Tipo Uroquinasa/efectos de los fármacos , Animales , Modelos Animales de Enfermedad , Regulación hacia Abajo , Femenino , Humanos , Masculino , Ratas , Ratas Sprague-Dawley , Sesquiterpenos/farmacologíaRESUMEN
PURPOSE: The high false positive rate (FPR) of 18F-FDG PET/CT in lung cancer screening represents a severe challenge for clinical decision-making. This study aimed to develop a clinical-translatable radiomics nomogram for reducing the FPR of PET/CT in lung cancer diagnosis, and to determine the impact of integrating manual diagnosis to the performance of the radiomics nomogram. METHODS: Among 3,947 18F-FDG PET/CT-screened patients with lung lesion, 157 malignant and 111 benign patients were retrospectively enrolled and divided into training and test cohorts. The data of manual diagnosis were recorded. A total of 4,338 features were extracted from CT, thin-section CT, PET and PET/CT, and the four radiomics signatures (RS) were then generated by LASSO method. Radiomics prediction nomogram integrating imaging-based RS and manual diagnosis was developed using multivariable logistic regression. The performances of RS and prediction nomograms were independently validated through key discrimination index and clinical benefit. RESULTS: The FPR of manual diagnosis was found to be 30.6%. Among the four RS, PET/CT RS exhibited the best performance. By integrating manual diagnosis, the hybrid nomogram integrating PET/CT RS and manual diagnosis demonstrated lowest FPR and highest area under curve (AUC) and Youden index (YI) in both training and test cohorts (FPR: 5.4% and 9.1%, AUC: 0.98 and 0.92, YI: 85.8% and 75.5%, respectively). This hybrid nomogram respectively corrected 78.6% and 37.5% among FPR cases produced by PET/CT RS, without significantly sacrificing its sensitivity. The net benefit of hybrid nomogram appeared highest at <85% threshold probability. CONCLUSION: The established hybrid nomogram integrating PET/CT RS and manual diagnosis can significantly reduce FPR, improve diagnostic accuracy and enhance clinical benefit compared to manual diagnosis. By integrating manual diagnosis, the performance of this hybrid nomogram is superior to PET/CT RS, indicating the importance of clinicians' judgement as an essential information source for improving radiomics diagnostic approaches.
Asunto(s)
Fluorodesoxiglucosa F18 , Procesamiento de Imagen Asistido por Computador/métodos , Neoplasias Pulmonares/diagnóstico por imagen , Tomografía Computarizada por Tomografía de Emisión de Positrones , Reacciones Falso Positivas , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Oxygen vacancy (Vo) on transition metal oxides plays a crucial role in determining their chemical/physical properties. Conversely, the capability to directly detect the changing process of oxygen vacancies (Vos) will be important to realize their full potentials in the related fields. Herein, with a novel synchronous illumination X-ray photoelectron spectroscopy (SI-XPS) technique, we found that the surface Vos (surf-Vos) exhibit a strong selectivity for binding with the water molecules, and sequentially capture an oxygen atom to achieve the anisotropic self-healing of surface lattice oxygen. After this self-healing process, the survived subsurface Vos (sub-Vos) promote the charge excitation from Ti to O atoms due to the enriched electron located on low-coordinated Ti sites. However, the excessive sub-Vos would block the charge separation and transfer to TiO2 surfaces resulted from the destroyed atomic structures. These findings open a new pathway to explore the dynamic changes of Vos and their roles on catalytic properties, not only in metal oxides, but in crystalline materials more generally.
RESUMEN
Autoimmune pathogenesis is responsible for a subset of primary ovarian insufficiency (POI) cases. The significance of autoantibodies for POI, however, remains unclear. A total of 250 women with idiopathic POI and 256 age-matched healthy women were enrolled. The presence in serum of adrenal cortex autoantibody (AAA), detected by indirect immunofluorescence and non-organ-specific antibodies, including antinuclear antibody, anti-cardiolipin antibody, and anti-double stranded DNA antibody, detected by enzyme-linked immunosorbent assay, was compared. Ovarian biopsy was carried out for histology assessment. Adrenal function was followed-up in 15 women with POI who were positive for AAA. Higher frequency of positive AAA was observed in women with POI (19.2%) compared with controls (5.9%, P < 0.01). No difference in anti-cardiolipin antibody, antinuclear antibody and anti-double stranded DNA antibody was found between the two groups. Ovarian biopsies in 13 women with POI (six AAA positive and seven negative) showed atrophic ovaries devoid of follicles. One out of fifteen women positive for AAA had symptoms of adrenal insufficiency 3 years after POI diagnosis. Significantly higher positive frequency of AAA in POI patients suggests the role of autoimmune disturbance in pathogenesis. Therefore, AAA may serve as a biomarker for ovarian autoimmunity.
Asunto(s)
Autoinmunidad , Insuficiencia Ovárica Primaria/inmunología , Adulto , Autoanticuerpos/sangre , Biopsia , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Ovario/patologíaRESUMEN
Vascular endothelial growth inhibitor (VEGI) is an anti-angiogenic protein, which includes three isoforms: VEGI-174, VEGI-192, and VEGI-251. The NGR (asparagine-glycine-arginine)-containing peptides can specifically bind to CD13 (Aminopeptidase N) receptor which is overexpressed in angiogenic blood vessels and tumor cells. In this study, a novel NGR-VEGI fusion protein was prepared and labeled with (188)Re for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts. Single photon emission computerized tomography (SPECT) imaging results revealed that (188)Re-NGR-VEGI exhibits good tumor-to-background contrast in CD13-positive HT-1080 tumor xenografts. The CD13 specificity of (188)Re-NGR-VEGI was further verified by significant reduction of tumor uptake in HT-1080 tumor xenografts with co-injection of the non-radiolabeled NGR-VEGI protein. The biodistribution results demonstrated good tumor-to-muscle ratio (4.98 ± 0.25) of (188)Re-NGR-VEGI at 24 h, which is consistent with the results from SPECT imaging. For radiotherapy, 18.5 MBq of (188)Re-NGR-VEGI showed excellent tumor inhibition effect in HT-1080 tumor xenografts with no observable toxicity, which was confirmed by the tumor size change and hematoxylin and eosin (H&E) staining of major mouse organs. In conclusion, these data demonstrated that (188)Re-NGR-VEGI has the potential as a theranostic agent for CD13-targeted tumor imaging and therapy.
Asunto(s)
Fibrosarcoma/radioterapia , Isótopos/metabolismo , Receptor Nogo 1/metabolismo , Renio/metabolismo , Miembro 15 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/metabolismo , Animales , Antígenos CD13/metabolismo , Línea Celular Tumoral , Femenino , Xenoinjertos/metabolismo , Humanos , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Péptidos/metabolismo , Cintigrafía/métodos , Distribución Tisular/fisiologíaRESUMEN
OBJECTIVE: The purpose of the study was to investigate the association between macrophage migration inhibitory factor (MIF) gene polymorphisms and gestational diabetes mellitus (GDM) in Han Chinese women. METHODS: In this study, 915 unrelated pregnant women were recruited, among whom 430 had GDM and 485 served as controls. The rs755622 in the MIF gene (MIF-173G/C) was detected by the polymerase chain reaction Tm-shift genotyping method with fluorescence melting curve analysis. The associations of rs755622 in MIF variants with plasma glucose and insulin levels in the oral glucose tolerance test (OGTT) as well as with with blood fat levels were investigated. RESULTS: The frequencies of genotypes and allele types of rs755622 in MIF were significantly different between women of the GDM and control groups (all p < 0.001). Moreover, the single nucleotide polymorphism (SNP) was significantly associated with increased glucose levels at 0, 60 and 120 min during the OGTT (all p < 0.0038) and with the increased homeostasis model assessment of insulin resistance (p < 0.001) in the GDM group. CONCLUSION: Genetic polymorphism of rs755622 in MIF is associated with increased risk of GDM and insulin resistance in Han Chinese women.
Asunto(s)
Diabetes Gestacional/sangre , Diabetes Gestacional/genética , Resistencia a la Insulina/genética , Oxidorreductasas Intramoleculares/genética , Factores Inhibidores de la Migración de Macrófagos/genética , Adulto , China , Femenino , Humanos , Polimorfismo de Nucleótido Simple , EmbarazoRESUMEN
Peptides containing asparagine-glycine-arginine (NGR) and arginine-glycine-aspartic acid (RGD) sequence are being developed for tumor angiogenesis-targeted imaging and therapy. The aim of this study was to compare the efficacy of NGR- and RGD-based probes for imaging tumor angiogenesis in HT-1080 tumor xenografts. Two PET probes, (68)Ga-NOTA-G3-NGR2 and 68Ga-NOTA-G3-RGD2, were successfully prepared. In vitro stability, partition coefficient, tumor cell binding, as well as in vivo biodistribution properties were also analyzed for both PET probes. The results revealed that the two probes were both hydrophilic and stable in vitro and in vivo, and they were excreted predominately and rapidly through the kidneys. For both probes, the higher tumor uptake and lower accumulation in vital organs were determined. No significant difference between two probes was observed in terms of tumor uptake and the in vivo biodistribution properties. We concluded that these two probes are promising in tumor angiogenesis imaging. 68Ga-NOTA-G3-NGR2 has the potential as an alternative for PET imaging in patients with fibrosarcoma, and it may offer an opportunity to noninvasively monitor CD13-targeted therapy.
Asunto(s)
Fibrosarcoma/irrigación sanguínea , Imagen Molecular , Neovascularización Patológica/diagnóstico por imagen , Oligopéptidos , Radiofármacos , Adenocarcinoma/irrigación sanguínea , Adenocarcinoma/diagnóstico por imagen , Animales , Transporte Biológico , Línea Celular Tumoral , Estabilidad de Medicamentos , Femenino , Fibrosarcoma/diagnóstico por imagen , Radioisótopos de Galio , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Ratones Desnudos , Oligopéptidos/química , Oligopéptidos/farmacocinética , Tomografía de Emisión de Positrones , Radiofármacos/química , Radiofármacos/farmacocinética , Eliminación Renal , Distribución Tisular , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Peptides containing the asparagines-glycine-arginine (NGR) motif have been identified as specific ligands binding to CD13/aminopeptidase N (APN) receptor, a tumor neovascular biomarker. In this study, we synthesized a novel NGR-containing peptide (NOTA-G3-NGR), and labeled NOTA-G3-NGR with (68)Ga (t1/2 = 67.7 min). The resulting (68)Ga-NOTA-G3-NGR peptide was subject to in vitro and in vivo characterization. The microPET imaging results revealed that the (68)Ga-NOTA-G3-NGR peptide exhibits rapid and specific tumor uptake, and high tumor-to-background contrast in a subcutaneous HT-1080 fibrosarcoma mouse model. We concluded that the (68)Ga-NOTA-G3-NGR peptide has potential in the diagnosis of CD13-targeted tumor angiogenesis.
Asunto(s)
Aminopeptidasas/metabolismo , Antígenos CD13/metabolismo , Radioisótopos de Galio , Imagen Molecular , Oligopéptidos , Tomografía de Emisión de Positrones , Aminopeptidasas/genética , Animales , Antígenos CD13/genética , Línea Celular Tumoral , Femenino , Radioisótopos de Galio/química , Expresión Génica , Xenoinjertos , Humanos , Ratones , Oligopéptidos/química , Oligopéptidos/metabolismo , Unión Proteica , Relación Señal-Ruido , Distribución TisularRESUMEN
The uMI Panorama is a novel PET/CT system using silicon photomultiplier and application-specific integrated circuit technologies and providing exceptional spatial and time-of-flight (TOF) resolutions. The objective of this study was to assess the physical performance of the uMI Panorama in accordance with the National Electrical Manufacturers Association (NEMA) NU 2-2018 standard. Methods: Spatial resolution, sensitivity, count rate performance, accuracy, image quality, and TOF resolution were evaluated in accordance with the guidelines outlined in the NEMA NU 2-2018 standard. Energy resolution was determined using the same dataset acquired for the count rate performance evaluation. Images from a Hoffman brain phantom, a mini-Derenzo phantom, and 3 patient studies were evaluated to demonstrate system performance. Results: The transaxial spatial resolution at full width at half maximum was measured as 2.88 mm with a 1-cm offset from the center axial field of view. The sensitivity at the center axial field of view was 20.1 kcps/MBq. At an activity concentration of 73.0 kBq/mL, the peak noise-equivalent count rate (NECR) reached 576 kcps with a scatter fraction of approximately 33.2%. For activity concentrations at or below the peak NECR, the maximum relative count rate error among all slices remained consistently below 3%. When assessed using the NEMA image quality phantom, overall image contrast recovery ranged from 63.2% to 88.4%, whereas background variability ranged from 4.2% to 1.1%. TOF resolution was 189 ps at 5.3 kBq/mL and was consistently lower than 200 ps for activity concentrations at or below the peak NECR. The patient studies demonstrated that scans at 2 min/bed produced images characterized by low noise and high contrast. Clear delineation of nuclei, spinal cords, and other substructures of the brain was observed in the brain PET images. Conclusion: uMI Panorama, the world's first commercial PET system with sub-200-ps TOF resolution, demonstrated fine spatial and fast TOF resolutions, robust count rate performance, and high quantification accuracy across a wide range of activity levels. This advanced technology offers enhanced diagnostic capability for detecting small and low-contrast lesions while showing promising potential under high-count-rate imaging scenarios.
RESUMEN
Brain PET imaging often faces challenges from head motion (HM), which can introduce artifacts and reduce image resolution, crucial in clinical settings for accurate treatment planning, diagnosis, and monitoring. United Imaging Healthcare has developed NeuroFocus, an HM correction (HMC) algorithm for the uMI Panorama PET/CT system, using a data-driven, statistics-based approach. The HMC algorithm automatically detects HM using a centroid-of-distribution technique, requiring no parameter adjustments. This study aimed to validate NeuroFocus and assess the prevalence of HM in clinical short-duration 18F-FDG scans. Methods: The study involved 317 patients undergoing brain PET scans, divided into 2 groups: 15 for HMC validation and 302 for evaluation. Validation involved patients undergoing 2 consecutive 3-min single-bed-position brain 18F-FDG scans-one with instructions to remain still and another with instructions to move substantially. The evaluation examined 302 clinical single-bed-position brain scans for patients with various neurologic diagnoses. Motion was categorized as small or large on the basis of a 5% SUV change in the frontal lobe after HMC. Percentage differences in SUVmean were reported across 11 brain regions. Results: The validation group displayed a large negative difference (-10.1%), with variation of 5.2% between no-HM and HM scans. After HMC, this difference decreased dramatically (-0.8%), with less variation (3.2%), indicating effective HMC application. In the evaluation group, 38 of 302 patients experienced large HM, showing a 10.9% ± 8.9% SUV increase after HMC, whereas most exhibited minimal uptake changes (0.1% ± 1.3%). The HMC algorithm not only enhanced the image resolution and contrast but also aided in disease identification and reduced the need for repeat scans, potentially optimizing clinical workflows. Conclusion: The study confirmed the effectiveness of NeuroFocus in managing HM in short clinical 18F-FDG studies on the uMI Panorama PET/CT system. It found that approximately 12% of scans required HMC, establishing HMC as a reliable tool for clinical brain 18F-FDG studies.
Asunto(s)
Algoritmos , Encéfalo , Procesamiento de Imagen Asistido por Computador , Tomografía Computarizada por Tomografía de Emisión de Positrones , Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Procesamiento de Imagen Asistido por Computador/métodos , Encéfalo/diagnóstico por imagen , Adulto , Fluorodesoxiglucosa F18 , Artefactos , Cabeza/diagnóstico por imagen , Anciano de 80 o más Años , Adulto JovenRESUMEN
CD13 receptor plays a critical role in tumor angiogenesis and metastasis. We therefore aimed to develop (99m)Tc-labeled monomeric and dimeric NGR-containing peptides, namely, NGR1 and NGR2, for SPECT imaging of CD13 expression in HepG2 hepatoma xenografts. Both NGR-containing monomer and dimer were synthesized and labeled with (99m)Tc. In vivo receptor specificity was demonstrated by successful blocking of tumor uptake of (99m)Tc-NGR dimer in the presence of 20 mg/kg NGR2 peptide. Western blot and immunofluorescence staining confirmed the CD13 expression in HepG2 cells. The NGR dimer showed higher binding affinity and cell uptake in vitro than the NGR-containing monomer, presumably due to a multivalency effect. (99m)Tc-Labeled monomeric and dimeric NGR-containing peptides were subjected to SPECT imaging and biodistribution studies. SPECT scans were performed in HepG2 tumor-bearing mice at 1, 4, 12, and 24 h post-injection of ~7.4 MBq tracers. The metabolism of tracers was determined in major organs at different time points after injection which demonstrated rapid, significant tumor uptake and slow tumor washout for both traces. Predominant clearance from renal and hepatic system was also observed in (99m)Tc-NGR1 and (99m)Tc-NGR2. In conclusion, monomeric and dimeric NGR peptide were developed and labeled with (99m)Tc successfully, while the high integrin avidity and long retention in tumor make (99m)Tc-NGR dimer a promising agent for tumor angiogenesis imaging.
Asunto(s)
Antígenos CD13/metabolismo , Carcinoma Hepatocelular/diagnóstico por imagen , Neoplasias Hepáticas Experimentales/diagnóstico por imagen , Oligopéptidos , Compuestos de Organotecnecio , Péptidos , Radiofármacos , Animales , Carcinoma Hepatocelular/metabolismo , Estabilidad de Medicamentos , Células HT29 , Células Hep G2 , Humanos , Neoplasias Hepáticas Experimentales/metabolismo , Ratones , Trasplante de Neoplasias , Oligopéptidos/metabolismo , Oligopéptidos/farmacocinética , Compuestos de Organotecnecio/metabolismo , Compuestos de Organotecnecio/farmacocinética , Péptidos/metabolismo , Péptidos/farmacocinética , Radiofármacos/metabolismo , Radiofármacos/farmacocinética , Distribución Tisular , Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
Several recent works have tackled the estimation issue for the unidimensional four-parameter logistic model (4PLM). Despite these efforts, the issue remains a challenge for the multidimensional 4PLM (M4PLM). Fu et al. (2021) proposed a Gibbs sampler for the M4PLM, but it is time-consuming. In this paper, a mixture-modelling-based Bayesian MH-RM (MM-MH-RM) algorithm is proposed for the M4PLM to obtain the maximum a posteriori (MAP) estimates. In a comparison of the MM-MH-RM algorithm to the original MH-RM algorithm, two simulation studies and an empirical example demonstrated that the MM-MH-RM algorithm possessed the benefits of the mixture-modelling approach and could produce more robust estimates with guaranteed convergence rates and fast computation. The MATLAB codes for the MM-MH-RM algorithm are available in the online appendix.
Asunto(s)
Algoritmos , Teorema de Bayes , Simulación por Computador , Modelos LogísticosRESUMEN
Tenvermectin (TVM) is a novel 16-membered macrolide compound isolated and purified from the fermentation broth of genetically engineered Streptomyces avermitilis strain MHJ1011. TVM and ivermectin were administered at the dose of 0.3 mg/kg body weight through a single subcutaneous injection route followed by plasma collectiom and analysis at different time intervals. Plasma concentrations of TVM and IVM were determined by high-performance liquid chromatography with fluorescence detector. Pharmacokinetic analysis was completed using the non-compartmental method with WinNonlin™ 6.4 software. TVM is rapidly absorbed after administration with peak plasma concentrations (Cmax , 9.78 ± 2.34 ng/ml) obtained within 6-22 h. AUC0-last was 586.86 h·ng/ml ± 121.24 h·ng/ml. The mean elimination half-life of TVM (T1/2λz ) was 97.99 h ± 46.41 h. The T1/2λz of IVM was 146.59 h ± 22.26 h in the study. The present study showed that subcutaneous administration of TVM at 0.3 mg/kg body weight (BW) in swine is absorbed more rapidly than IVM in swine. Compared to the pharmacokinetic characteristics of IVM, there was little difference in the half-life of TVM among different individuals. The data will contribute to refining the formulation and dosage regime for TVM administration.